SecBot SecBot
8-K ·Filed May 7, 2026

VERA

Vera Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-210351
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The widening loss and cash burn are expected for a pre-commercial biotech, but the stock will trade on the PDUFA date (July 7, 2026) and PIONEER Phase 2 data (expected Q2 2026). Monitor for any FDA advisory committee meeting announcement or label expansion data.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$35.88
T+0 close · May 7, 2026 · via day close
Latest settled
−10.17%
T+60 · $32.23
Vs SPY
−14.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $35.88entry
  2. T+1 · 6mo ago +0.86%α +0.03% · $36.19
  3. T+5 · 6mo ago +9.11%α +7.61% · $39.15
  4. T+20 · 6mo ago −12.85%α −15.98% · $31.27
  5. T+60 · 4mo ago −10.17%α −14.01% · $32.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, driven by increased R&D and G&A spending ahead of a potential atacicept launch. The company maintains a strong cash position of $596.8M and is on track for a mid-2026 U.S. commercial launch pending FDA approval by July 7, 2026.

Key Financial Metrics

EPS
−$1.69
Rating
in line

Key Facts

  • Net loss per diluted share of $1.69 for Q1 2026 vs $0.81 in Q1 2025
  • Cash, cash equivalents, and marketable securities of $596.8M as of March 31, 2026
  • FDA PDUFA target action date for atacicept BLA is July 7, 2026
  • Company expects U.S. commercial launch of atacicept in mid-2026, pending approval
  • Net cash used in operating activities was $106.5M in Q1 2026 vs $54.4M in Q1 2025

Financial Impact

Net loss widened to $121.0M from $51.7M YoY; cash burn increased to $106.5M from $54.4M

net lossoperating cash flowcash position

Risk Factors

  • FDA non-approval or delay of atacicept BLA
  • Higher-than-expected cash burn rate could require additional financing
  • Competitive landscape in IgA nephropathy

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-210351
Document: vera-20260507.htm0001193125-26-210351
Document: 0001193125-26-210351-index-headers.html0001193125-26-210351
Document: 0001193125-26-210351-index.html0001193125-26-210351
Document: 0001193125-26-210351.txt0001193125-26-210351
8-K Data (Synthetic)0001193125-26-210351

Track record

25 reports on VERA

Performance horizon

13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (10h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026